What is the standard FDA response window for a warning letter?

FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.

criticalHuman Foods Program· Labeling / misbranded

OptiHealth Products, Inc. — FDA Warning Letter, 2026-04-29: New Drug/Misbranded

Name: FDA Warning Letter Record — OptiHealth Products, Inc.
Creator: Argus HQ
License: https://argushq.ai/methodology

Letter issued 2026-04-29 · posted to fda.gov 2026-05-12.

Subject as published: New Drug/Misbranded

TL;DR

Here's the summary: FDA issued a Warning Letter to OptiHealth Products, Inc. on 2026-04-29 citing: New Drug/Misbranded. Full letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/optihealth-products-inc-704899-04292026

Argus analysis

OptiHealth Products, Inc. (MARCS-CMS 704899) received an FDA Warning Letter dated April 29, 2026 from the Human Foods Program. The letter cites: New Drug/Misbranded. FDA posts Warning Letters to fda.gov after an internal review period; this one was made public on May 12, 2026.

Labeling letters cite 21 USC 343 (food misbranding) or 21 USC 352 (drug misbranding), most often over disease-treatment claims made in labeling or marketing copy that push a product out of its stated category. Most peer companies resolve these by revising SKU-level claims within the response window rather than reformulating the product itself.

FDA Warning Letters typically specify a 15-working-day response window for the recipient to detail corrective actions. Compliance teams at peer companies in the same labeling/misbranding category commonly use a newly published letter as a prompt to re-check their own procedures against the same citation, and to watch fda.gov for a close-out letter confirming the cited firm's corrective action was accepted — or, absent one, for escalation to import alert, injunction, or product seizure.

Severity context

Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.

Regulatory background

Labeling letters cite 21 USC 343 (food), 21 USC 352 (drugs), or 21 USC 352 (devices). Most are resolved by SKU-level copy revision within the 15-business-day response window.

What peer compliance teams typically do next

Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.

Excerpt from the FDA Warning Letter (public domain, 17 USC §105)

WARNING LETTER OptiHealth Products, Inc. MARCS-CMS 704899 — April 29, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Product: Dietary Supplements Recipient: Recipient Name Mr. Russell Dickson Recipient Title President OptiHealth Products, Inc. 275 River Rd Saint James , NY 11780 United States support@optihealthstore.com Issuing Office: Human Foods Program United States April 29, 2026 WARNING LETTER CMS # 704899 Dear Mr. Dickson: The U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https://optihealthproducts.com in December 2025 and has determined that you take orders there for your product Super Antioxidant (OPCXtra). We also reviewed your social media website at https://www.facebook.com/OptiHealthProducts where you direct consumers to your website, https://optihealthproducts.com/ to purchase your products. The claims on your website, https://optihealthproducts.com/ establish that this product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov. Examples of some of the claims that provide evidence that your product is intended for use as a drug include: “ 6 Remarkable Benefits of Bilberry Extract 1 ” https://optihealthproducts.com/blogs/news/6-remarkable-benefits-of-bilberry-extract Under the section, “Heart Health Support” o “The antioxidants in bilberries are believed to help reduce the risk of heart disease by improving blood vessel function, reducing blood pressure, and lowering cholesterol levels…” Under the section, “Diabetes Management” o “Bilberry extract has shown promise in helping regulate blood sugar levels, making it a potential ally for individuals with diabetes or those at risk of developing the condition…” Under the section, “Anti- Inflammatory Properties” o “Chronic inflammation is linked to a wide range of health issues, from arthritis to cancer. Bilberry's anti-inflammatory properties, may help alleviate inflammation and reduce the risk of chronic diseases associated with prolonged inflammation.” “Antioxidants and Aging: The Key to a Youthful Glow and Enhance Health” https://optihealthproducts.com/blogs/news/antioxidants-and-aging-the-key-to-a-youthful-glow-and-enhanced-health Under the section, “Cognitive Function” o “Antioxidants can help reduce oxidative damage in brain cells, potentially lowering the risk of age-related cognitive decline and diseases like Alzheimer's.” Under the section, “Cardiovascular Health” o “Antioxidants like flavonoids and vitamin E can improve heart health by reducing oxidation of cholesterol, lowering blood pressure, and impr…

Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.

The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.

Read the full letter on fda.gov ↗

Frequently asked questions

Is the FDA warning letter to OptiHealth Products, Inc. publicly available?: Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/optihealth-products-inc-704899-04292026.
What does a "critical" severity rating mean for this letter?: Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
What is the regulatory background for a Labeling / misbranded warning letter?: Labeling letters cite 21 USC 343 (food), 21 USC 352 (drugs), or 21 USC 352 (devices). Most are resolved by SKU-level copy revision within the 15-business-day response window.
What is the standard FDA response window for a warning letter?: FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.

argus.hq

Don’t find out about the next one six weeks late.

Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.

Start the daily brief See a sample

methodology

The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.

Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). OptiHealth Products, Inc. — FDA Warning Letter, 2026-04-29: New Drug/Misbranded. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-optihealth-products-inc-2026-04-29-labeling

MLA

"OptiHealth Products, Inc. — FDA Warning Letter, 2026-04-29: New Drug/Misbranded." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-optihealth-products-inc-2026-04-29-labeling.

Chicago

Argus HQ Research. "OptiHealth Products, Inc. — FDA Warning Letter, 2026-04-29: New Drug/Misbranded." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-optihealth-products-inc-2026-04-29-labeling.

BibTeX

@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_optihealth_products_inc_2026_04_29_labeling_2026,
  title = {OptiHealth Products, Inc. — FDA Warning Letter, 2026-04-29: New Drug/Misbranded},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/fda/warning-letter/fda-wl-optihealth-products-inc-2026-04-29-labeling},
  note = {Accessed: July 13, 2026}
}